Email this article Kompleksnaya terapiya pri aterogennoydislipidemii i nealkogol'noy zhirovoybolezni pecheni
- Authors: Cherkashova E.A.1, Zvenigorodskaya L.A.1, Samsonova N.G.1, Nilova T.V.1, Sil'vestrova S.Y.1, Khomeriki S.G.1
-
Affiliations:
- Issue: Vol 2, No 1 (2011)
- Pages: 29-36
- Section: Articles
- URL: https://cardiosomatics.ru/2221-7185/article/view/44962
- DOI: https://doi.org/10.26442/CS44962
- ID: 44962
Cite item
Full Text
Abstract
Summary. Non-alcoholic fatty liver disease (NAFLD) is one of the major components of the metabolic syndrome.
NAFLD is now recognized as one of the major cardiovascular risk factors since cholesterol synthesis takes place in
the liver. In this connection, to choose hypolipidemic therapy that has well-known hepatotoxic effects is an intricate
problem. Of great importance in the pathogenesis of NAFLD is the impaired colonic microflora and hence elevated
levels of microbial waste products (short-chain fatty acids, endotoxin, nitric oxide), which should be also
kept in mind when treating atherogenic dyslipidemia. Statin + probiotic combination therapy used in patients with
NAFLD and atherogenic dyslipidemia is more effective than monotherapy in reducing the levels of cholesterol and
intestinal microflora metabolism products.
NAFLD is now recognized as one of the major cardiovascular risk factors since cholesterol synthesis takes place in
the liver. In this connection, to choose hypolipidemic therapy that has well-known hepatotoxic effects is an intricate
problem. Of great importance in the pathogenesis of NAFLD is the impaired colonic microflora and hence elevated
levels of microbial waste products (short-chain fatty acids, endotoxin, nitric oxide), which should be also
kept in mind when treating atherogenic dyslipidemia. Statin + probiotic combination therapy used in patients with
NAFLD and atherogenic dyslipidemia is more effective than monotherapy in reducing the levels of cholesterol and
intestinal microflora metabolism products.
About the authors
Elizaveta Andreevna Cherkashova
Larisa Arsent'evna Zvenigorodskaya
Natal'ya Gennad'evna Samsonova
Tamara Vasil'evna Nilova
Svetlana Yur'evna Sil'vestrova
Sergey Germanovich Khomeriki
References
- Карнаушкина М.А. Бронхиальная проходимость у больных крапивницей и токсикодермией. Автореф. дис. … канд. мед. наук. М., 1997.
- Коннов П.Е. Состояние органов пищеварения и гуморальных факторов иммунитета при экзематозном процессе с сенсибилизацией к пыльцевым аллергенам. Автореф. дис. … канд. мед. наук. Самара, 2003.
- Kruger S, Kunz D, Graf J et al. Endotoxin sensitivity and immune competence in chronic heart failure. Clin Chim Acta 2004; 343 (1-2): 135-9.
- Sontag SJ, O'Connell S, Khandelwal S et al. Most asthmatics have gastroesophageal reflux with or without bronchodilator therapy. Gastroenterology 1990; 99 (3): 613-20.
- Heaton KW. The role of the large intestine in cholesterol gallstone formation. Bile acids in hepatobiliary diseases. Eds.: T.Northfield, H.Ahmed, R.Jazrawl, P.Zeutler-Munro. Dordrecht: Kluwer Publisher, 2000; p. 192-9.
- Ардатская М.Д. Диагностическое значение содержания короткоцепочечных жирных кислот при синдроме раздражен- ного кишечника. Рос. журн. гастроэнтерол., гепатол. и колопроктол. 2000; 10 (3): 36-41.
- Jenkins DJA, Kendall CWC, Vuksan V. Inulin, Oligofructose and Intestinal Function. J Nutr 1999; 129: 1431-3.
- Джанашия П.Х., Назаренко В.А., Николенко С.А. Дислипопротеидемии: клиника, диагностика, лечение. М.: РГМУ, 2000.
- Husebye E, Hellstrom R, Midtvedt T. The role of normal microbial flora in control of small intestine motility. Microbiol Therapy 1990; 20: 389-94.
- Conraads VM, Jorens PG, De Clerck LS et al. Selective intestinal decontamination in advanced chronic heart failure a pilot study. Europ J Heart Fail 2004; 6: 483-91.
- Wigg AJ, Robert-Thompson JG, Dymock RB. The role small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia and tumor necrosis factor - alfa in a pathogenesis of nonalcoholic steatohepatitis. Gut 2001; 48: 206-11.
- Ткаченко Е.И., Успенский Ю.П. Питание, микробиоценоз и интеллект человека. Санкт-Петербург: СпецЛит., 2006.
- Rolfe RD. Interactions among microorganisms of the indigenous intestinal flora and their influence on the host. Rev Infect Dis 1984; 6 (Suppl. 1): S73-9.
- Карнейро де Мур М. Неалкогольный стеатогепатит. Клин. перспективы в гастроэнтерологии, гепатологии. 2001; 2: 12-5.
- Cherbut C, Aube AC, Blottiere HM, Galmiche JP. Effects of shortchain fatty acids on gastrointestinal motility. Scand J Gastroenterol 1997; 32 (Suppl. 222): 58-61.
- Артюнов Г.А., Кафарская Л.И., Власенко В.К. и др. Биоценоз кишечника и сердечно-сосудистый континуум. Сердечная недостаточность. 2004; 5 (5): 224-9.
- Конев Ю.В., Лазебник Л.Б., Яковлев М.Ю. и др. Атеросклероз и эндотоксин. Клин. геронтология. 2004; 7: 36-42.
- Репин В.С., Сухих Г.Т. Медицинская клеточная биология. М., 1998.
- Ткаченко Е.И., Суворова А.Н. Дисбиоз кишечника. Руководство по диагностике и лечению. СПб.: СпецЛит. 2007.
- Midtvedt T, Lingaas E, Carlstedt-Duke B et al. Intestinal microbial conversion of choles-terol to coprostanol mark. Influence of antibiotics. Acta Path Microjbial 1990; 98: 967-81.
- Клеменов А.В., Мартынов В.Л. Хроническая дуоденальная непроходимость и дисбактериоз кишечника как факторы па- тогенеза бронхиальной астмы у больных с несостоятельностью илеоцекального клапана. Аллергология. 2003; (1): 23-6.
Supplementary files
